NLRP3 and familial dilated cardiomyopathy: Inhibition of ACE-mediated NOX4-related OS and NLRP3 inflammasome activation in cardiac fibroblasts improves diabetic cardiac fibrosis, thereby providing a potential therapeutic approach for treating DCM.